4.38
+0.03(+0.69%)
Currency In USD
| Previous Close | 4.35 |
| Open | 4.47 |
| Day High | 4.6 |
| Day Low | 4.33 |
| 52-Week High | 5.9 |
| 52-Week Low | 0.6 |
| Volume | 1.2M |
| Average Volume | 2.01M |
| Market Cap | 357.67M |
| PE | -8.59 |
| EPS | -0.51 |
| Moving Average 50 Days | 3.18 |
| Moving Average 200 Days | 1.62 |
| Change | 0.03 |
If you invested $1000 in I-Mab (IMAB) since IPO date, it would be worth $350.4 as of September 07, 2025 at a share price of $4.38. Whereas If you bought $1000 worth of I-Mab (IMAB) shares 3 years ago, it would be worth $767.08 as of September 07, 2025 at a share price of $4.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee
GlobeNewswire Inc.
Aug 25, 2025 11:00 AM GMT
Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of DirectorsResearch and Development Committee established to accelerate innovation and long-term growthDr. Ken Takeshita appointed to the Scientific Advisory Board ROCKVILLE, Md.,
I-Mab to Participate in September Investor Conferences
GlobeNewswire Inc.
Aug 21, 2025 11:00 AM GMT
ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s m
I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers
GlobeNewswire Inc.
Aug 11, 2025 11:00 AM GMT
Enrollment in the planned second dose expansion cohort completed ahead of expectationsTopline results expected in Q1 2026 Positive Phase 1b dose escalation data presented at ESMO GI on July 2nd ROCKVILLE, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- I-Ma